Research directed toward developing immune-recovery treatment based on inhibiting a glycosidease
| Project/Area Number |
15K14399
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
Kanie Osamu 東海大学, 先進生命科学研究所, 教授 (90291062)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
INOUE Shigeaki 東海大学, 医学部, 准教授 (30582209)
TANAKA Katsunori 独立行政法人理化学研究所, 田中生体機能合成化学研究室, 準主任研究員 (00403098)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 高齢化 / がん / 敗血症 / 免疫療法 / 酵素阻害 / マクロファージ / マクロファージ活性化因子 / αガラクトサミニザーゼ / 酵素阻害剤 / αガラクトサミニダーゼ |
|---|
| Outline of Final Research Achievements |
A partially truncated O-glycan-carrying Gc protein is known to activate immunity as GcMAF. It is expected that controlling the blood stability of GcMAF might affect the immune response against tumor. For this reason, a research directed toward finding a new therapeutic method based on inhibition of a key enzyme, α-GalNAc-ase was carried out.
Investigation of human α-GalNase activity and the inhibitory activity of a synthetic inhibitor revealed that the particular enzyme was stored in lysosome and was inhibited by the inhibitor. It is expected that the inhibitor molecule might be potent to maintain blood-GcMAF level. The presence of α-GalNAc structure in the GcMAF was also confirmed based on mass spectrometric analysis.
|
Report
(3 results)
Research Products
(5 results)
